NSAID patch, Diclo, launched in Korea

Published: 2008-02-13 06:56:00

Updated: 2008-02-13 06:56:00

Chong Kun Dang Pharmaceuticals has launched Diclo, a transdermal patch containing diclofenac diethylammonium, a non-steroidal anti-inflammatory drug for the treatment of musculo-skeletal and other inflammation related conditions, in the domestic market.

Diclo is a matrix drug-in adhesive patch...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK